EGFR and neoplasm: Gefitinib (ZD1839, Iressa), a selective inhibitor of EGFR tyrosine kinase (EGFR-TKI) which is competitive with the combination of EGFR tyrosine kinase, acts through blocking the signal transduction pathway of epithelial growth factor and thereby inhibiting the proliferation and metastasis, and, promoting the apoptosis of tumor cells [1].